Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
PHASE1
This phase I trial studies the side effects and best dose of mosunetuzumab ...
Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment
PHASE2
This phase II trial compares the effect of mosunetuzumab alone to mosunetuz...
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
PHASE1
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) admi...
Status
Completed
Location
University of California San Diego Moores Cancer Center
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
PHASE1
This study will evaluate the safety, pharmacokinetics, and preliminary effi...
Status
Completed
Location
University of Alabama at Birmingham School of Medicine